Roth Capital Partners is pleased to invite you to our Roth Inaugural Healthcare Opportunities Conference to be held at the The Yale Club in New York City, NY on October 6th, 2022. This event will consist of 10 minute Company Presentations introduced by Roth Research Analysts as well as 1-on-1/ small group meetings. This format will provide an opportunity for C-level executives representing public healthcare companies in the Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therapeutics to tell their stories to investors.
For more information visit:
Conference Website
- Adaptimmune Therapeutics plc
- Assertio Holdings, Inc.
- Assure Holdings Corp.
- Atai Life Sciences N.V.
- Beyond Air, Inc.
- Biofrontera Inc.
- BioRestorative Therapies, Inc.
- Charge Enterprises Inc.
- Clene Inc.
Adaptimmune Therapeutics plc (NASDAQ: ADAP)
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. For more information visit the company's website at: www.adaptimmune.com
Assertio Holdings, Inc. (NASDAQ: ASRT)
Assertio Holdings, Inc. (NASDAQ: ASRT) is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through business development including licensing, mergers, and acquisitions. For more information visit the company's website at: www.assertiotx.com
Assure Holdings Corp. (NASDAQ: IONM)
Assure Holdings Corp. (NASDAQ: IONM) is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission's Gold Seal of Approval®. For more information visit the company's website at: www.assureneuromonitoring.com
Atai Life Sciences N.V. (NASDAQ: ATAI)
Atai Life Sciences N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. atai has offices in New York, London, and Berlin. For more information visit the company's website at: www.atai.life
Beyond Air, Inc. (NASDAQ: XAIR)
Beyond Air, Inc. (NASDAQ: XAIR) is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit®, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit® can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit® for clinical trials for the treatment of severe lung infections such as acute viral pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM). Additionally, Beyond Air, through its affiliate, Beyond Cancer, is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information visit the company's website at: www.beyondair.net
Biofrontera Inc. (NASDAQ: BFRI)
Biofrontera Inc. (NASDAQ: BFRI) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information visit the company's website at: www.biofrontera-us.com
BioRestorative Therapies, Inc. BRTX)
BioRestorative Therapies, Inc. (BRTX) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Their two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: Disc/Spine Program (brtxDISC ™ ): Their lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. They intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. Pursuant to authorization received from the Food and Drug Administration, they have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. Metabolic Program (ThermoStem ® ): They are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. For more information visit the company's website at: www.biorestorative.com
Charge Enterprises Inc. (NASDAQ: CRGE)
Charge Enterprises Inc. (NASDAQ: CRGE) consists of a portfolio of global businesses with a vision of connecting people everywhere with communications and electric vehicle charging infrastructure. Charge believes the rise of new developing technologies at the crossover of these industries offer them a unique growth opportunity. Their Telecommunications business has provided routing of both voice, data and short message services ("SMS") to carriers and mobile network operators ("MNOs") globally for over two decades and is poised to selectively add profitable products and services to this long-established business. Their Infrastructure business has a primary focus on two fast growing sectors: broadband, including cell tower, small cell, and in-building applications, and electric vehicle ("EV") charging. Solutions for these two sectors include: design and engineering, equipment specification and sourcing, installation, data and software solutions, and service and maintenance. For more information, visit the company's website at: www.charge.enterprises
Clene Inc. (NASDAQ: CLNN)
Clene Inc. (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure, an underlying cause of many neurological diseases. Their lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is currently being evaluated in a Phase 3 registration trial in amyotrophic lateral sclerosis (ALS) and a Phase 2 trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information visit the company's website at: www.clene.com
Delcath Systems, Inc. (NASDAQ: DCTH)
Delcath Systems, Inc. (NASDAQ: DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA). In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. For more information visit the company's website at: www.delcath.com
First Wave BioPharma, Inc. (NASDAQ: FWBI)
First Wave BioPharma, Inc. (NASDAQ: FWBI) is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. First Wave BioPharma's niclosamide portfolio is led by two clinical programs in Phase 2 clinical trials: FW-COV, for COVID-19 gastrointestinal infections and FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis. Three additional indications of niclosamide, include FW-ICI-AC, for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients, FW-UC (ulcerative colitis) and FW-CD (Crohn's disease). The Company is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit the company's website at: www.firstwavebio.com
Genenta Sciences (NASDAQ: GNTA)
Genenta Sciences (NASDAQ: GNTA) is a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Their platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro-environment. Genenta's lead product candidate, Temferon, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance. Their treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics. For more information, visit the company's website at: www.genenta.com
HeartBeam, Inc. (NASDAQ: BEAT)
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. The Company's breakthrough solution employs a reusable, credit card-sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack. For more information, visit the company's website at: www.heartbeam.com
Helius Medical Technologies (NASDAQ: HSDT)
Helius Medical Technologies (NASDAQ: HSDT) is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain's ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information visit the company's website at: heliusmedical.com
Journey Medical Corporation (NASDAQ: DERM)
Journey Medical Corporation (NASDAQ: DERM) is focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The company currently markets seven products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). Journey is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission ("SEC"). For more information visit the company's website at: www.journeymedicalcorp.com
Monopar Therapeutics, Inc. (NASDAQ: MNPR)
Monopar Therapeutics, Inc. (NASDAQ: MNPR) is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information visit the company's website at: www.monopartx.com
NextCure Inc. (NASDAQ: NXTC)
NextCure Inc. (NASDAQ: NXTC) is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, NextCure studies various immune cells to discover and understand targets and structural components of immune cells and their impact on immune function in order to develop immunomedicines. NextCure is focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. For more information visit the company's website at: www.nextcure.com
Nuvectis Pharma, Inc. (NASDAQ: NVCT)
Nuvectis Pharma, Inc. (NASDAQ: NVCT) is a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates: NXP800, a clinical-stage HSF1 pathway inhibitor currently in a Phase 1 study in patients with advanced solid tumors, and NXP900, a novel SRC/YES1 kinase inhibitor currently in preclinical development with IND-enabling studies ongoing. For more information, visit the company's website at: www.nuvectis.com
Panbela Therapeutics (NASDAQ: PBLA)
Panbela Therapeutics (NASDAQ: PBLA) is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents in other cancer indications. For more information visit the company's website at: www.panbela.com
RegeneRx Biopharmaceuticals, Inc. (OTCPK: RGRX)
RegeneRx Biopharmaceuticals, Inc. (OTCPK: RGRX) is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T?4) and its constituent fragments, for tissue and organ protection, repair, and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, acute inflammatory and dermal indications, four active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and the EU, and has patents and patent applications covering its products in many countries throughout the world. For more information visit the company's website at: www.regenerx.com
RenovoRx, Inc. (NASDAQ: RNXT)
RenovoRx, Inc. (NASDAQ: RNXT) is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx's lead product candidate, RenovoGemTM, is a combination of gemcitabine and their patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC. RenovoRx's patent portfolio includes seven U.S. patents for its technology. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer. RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology. For more information visit the company's website at: www.renovorx.com
Revelation Biosciences, Inc. (NASDAQ: REVB)
Revelation Biosciences, Inc. (NASDAQ: REVB) is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99a, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99b is being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation's therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation. For more information visit the company's website at: www.RevBiosciences.com
Sernova Corp. (OTC: SEOVF)
Sernova Corp. (OTC: SEOVF) is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information visit the company's website at: www.sernova.com
Stemtech Corporation (OTCQB: STEK)
Stemtech Corporation (OTCQB: STEK), a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Company's patented formulas help the release, circulation and migration of the body's adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem, OraStem® (Oral Health Care), and D-Fuze™ (EMF blocker). Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, visit the company's website at: www.stemtech.com
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP)
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally. For more information visit the company's website at: www.tffpharma.com
Unicycive Therapeutics, Inc. (NASDAQ: UNCY)
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information visit the company's website at: www.unicycive.com